Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| HSBC Holdings | 1.73% | $16.96M | £218.16B | 44.94% | 80 Outperform | |
| GlaxoSmithKline | 1.48% | $14.47M | £90.34B | 57.77% | 77 Outperform | |
| Novartis AG | 1.44% | $14.13M | CHF244.33B | 31.88% | 80 Outperform | |
| Murata Manufacturing Co | 1.17% | $11.42M | ¥6.47T | 40.31% | 77 Outperform | |
| Standard Chartered | 1.14% | $11.13M | £39.78B | 71.70% | 77 Outperform | |
| ING GROEP | 1.12% | $10.94M | €69.38B | 49.79% | 61 Neutral | |
| Barclays | 1.06% | $10.40M | £65.36B | 58.86% | 78 Outperform | |
| Roche Holding AG | 1.06% | $10.32M | CHF294.92B | 46.36% | 73 Outperform | |
| AstraZeneca | 1.05% | $10.22M | $324.77B | 32.79% | 80 Outperform | |
| ArcelorMittal | 1.02% | $10.02M | €39.93B | 103.58% | 73 Outperform |